Trial studying safety and effects for Glaucoma
Official title A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage
ClinicalTrials.gov ID: NCT07770685
What this study is testing
What is ASP2767?
an investigational gene therapy being studied as a potential treatment for open-angle glaucoma is designed to use a harmless viral vector to deliver genes to retinal nerve cells so they produce proteins that may protect eye nerves
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if the new treatment is safe and to find the highest dose people can take without serious problems. It also looks at whether the treatment helps protect vision.
- Who it's for
- People who have open-angle glaucoma, a condition that damages the nerves in the eye.
- What's involved
- Participants will get one injection into one eye. They will also take medicine to prevent swelling and have regular eye exams and blood or urine tests.
- Time commitment
- The study lasts about one year after the injection, with visits to the clinic on specific days for checks.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 1 year
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant agrees not to participate in another treatment study until the 52-week visit has been completed.
- Participant is able and willing to comply with the study requirements and capable of completing the assessments, including all scheduled visits.
- Presence of glaucomatous VF defects in the study eye with corresponding damage to the optic nerve head (ONH) (confirmed by an independent central...
- An open iridocorneal drainage angle observed on gonioscopy (Shaffer grade ≥ 3)
- Phase 1 - Dose-Escalation part: advanced VF loss, defined as MD between -12 and -20 dB
You likely can't join if
- Participant has other optic nerve or retinal degenerative disease-causing vision loss, irrespective of whether it is currently treated or untreated.
- Participant has other known or suspected molecular diagnosis of macular, retinal, or optic nerve disease (e.g., pathogenic mutations in other genes)...
- Participant has visually significant cataract in the study eye.
- Participant has active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis (mild stable blepharitis is permitted).
- Participant is expected to require a change in IOP-lowering treatment within 6 weeks of screening and/or is anticipated to require a change in...
- Participant has history of
See the full eligibility criteria
Who can join
- Participant agrees not to participate in another treatment study until the 52-week visit has been completed.
- Participant is able and willing to comply with the study requirements and capable of completing the assessments, including all scheduled visits.
- Presence of glaucomatous VF defects in the study eye with corresponding damage to the optic nerve head (ONH) (confirmed by an independent central image reading center at screening)
- An open iridocorneal drainage angle observed on gonioscopy (Shaffer grade ≥ 3)
- Phase 1 - Dose-Escalation part: advanced VF loss, defined as MD between -12 and -20 dB
- Phase 2 - Dose-Expansion part: moderate to advanced VF loss, defined as MD between -6 and -20 dB
- At least 3 reliable VF tests (≤ 33% FLs and ≤ 15% FP) within the preceding 84 months, confirmed by the central image reading center, and excluding fields obtained before incisional glaucoma or cataract surgeries
- Evidence of VF function in at least 1 quadrant in the study eye
- BCVA ≥ 20/200 (≥ 35 ETDRS letters) at screening and confirmed on day 1 in the study eye
- At least 3 consecutive reliable optical coherence tomography (OCT) scans (peripapillary RNFL, GCC/macula) in the study eye within the preceding 84 months, confirmed by the central image reading center.
- Participant must have an IOP ≤ 21 mmHg on current therapy in the study eye (or participant's IOP is considered well controlled and will not require any additional medical or surgical treatment in the next 12 months).
- Not a women of childbearing potential (WOCBP) o. WOCBP who has a negative serum pregnancy test at screening, or urine pregnancy test on day 1, agrees to follow the contraceptive guidance from the time of informed...
- Female participant must not be breastfeeding or lactating starting at screening and throughout the study period.
- Female participant must not donate ova starting at first administration of study intervention and throughout the study period.
- Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period.
- Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period.
- Male participant must not donate sperm during the treatment period (up to week 52).
What rules you out
- Participant has other optic nerve or retinal degenerative disease-causing vision loss, irrespective of whether it is currently treated or untreated.
- Participant has other known or suspected molecular diagnosis of macular, retinal, or optic nerve disease (e.g., pathogenic mutations in other genes) that could confound the interpretation of the outcome of the study...
- Participant has visually significant cataract in the study eye.
- Participant has active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis (mild stable blepharitis is permitted).
- Participant is expected to require a change in IOP-lowering treatment within 6 weeks of screening and/or is anticipated to require a change in IOP-lowering treatment during the study in the study eye.
- Participant has history of
- closed or narrow angle (Shaffer grade ≤ 2), pigment dispersion, uveitic glaucoma, or congenital glaucoma
- cyclophotocoagulation laser treatment for glaucoma in the study eye
- ocular herpetic disease (including herpes simplex and zoster viruses) or disseminated/visceral herpes zoster infection
- allergy to fluorescein or povidone iodine
- history of steroid response (historic evidence of IOP increase with corticosteroid use)
- Participant has presence of IOI (≥ trace anterior chamber [AC] cell or flare), has active or has a history of idiopathic or autoimmune-associated uveitis in either eye.
- Participant has evidence of corneal opacification or lack of optical clarity in the study eye.
- Participant has refractive error greater than 8 diopters of spherical equivalent at screening in the study eye.
- Participant has choroidal neovascularization, central serous retinopathy, or any other type of retinal degeneration/diseases that may interfere with the study procedures, evaluations and outcome assessments.
- Participant has undergone any laser or intraocular surgery (i.e., cataract surgery or minimally invasive glaucoma surgery) in the study eye within 12 weeks and/or yttrium aluminum garnet capsulotomy within 4 weeks prior...
- Participant has a history of vitrectomy surgery in the study eye.
- Participant has a history of, or currently has, optic neuropathy not due to glaucoma, including traumatic or anterior ischemic optic neuropathy.
- Participant has presence of any other concurrent ocular disease in the study eye that would affect or confound study outcomes.
- Participant has any of the following medical conditions
- diabetes mellitus hemoglobin A1c (HbA1c) value of \> 7% at screening, with the following exception: If the HbA1c value is \> 7% and the participant has a normal creatinine, has no diabetic retinopathy, or diabetic...
- uncontrolled hypertension defined as an average systolic blood pressure \> 160 mmHg or an average diastolic blood pressure \> 100 mmHg (second set of measurements is permitted if the first average exceeds the values...
- history of malignancy other than basal cell carcinoma, unless it was treated successfully at least 2 years prior to inclusion in the study
- history of multiple sclerosis or other severe autoimmune conditions
- history of uncontrolled hepatitis, pancreatitis, cirrhosis, asthma, liver/kidney/heart failure, or uncontrolled thyroid disease or intracranial hypertension
- Participant is currently receiving systemic steroids (other than those related to the study), chemotherapy, immunosuppressive medications, monoclonal antibodies, or glucagon-like peptide-1 treatment.
- Participant is currently using drugs with known ocular toxicity or confounding effects on VF assessments (including but not limited to hydroxychloroquine [Plaquenil], chloroquine, amiodarone, ethambutol, isoniazid...
- Participant has received any prior treatment including gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or prior IVT treatment for any indication in either eye that may be considered...
- Participant is currently participating in an treatment clinical study or has received an investigational agent by ocular or systemic administration within 3 months or 5 half-lives, whichever is longer prior to the...
- Participant has any severe acute or chronic medical condition, psychiatric condition, physical examination finding or laboratory abnormality may interfere with the study procedures, evaluation and outcome assessments...
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 1 year per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.